International (18 Offers)
Molecular Formula: C225H348N48O68S2
Molecular Weight: 4813.03 g/mol
Brand: Dragon Pharma Peptide Line
Dragon Tirzepatide is a novel medication designed for the treatment of type 2 diabetes, and it is currently being investigated for potential applications in weight management. It is classified as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This dual action harnesses the complementary effects of both incretin hormones to improve glycemic control and support metabolic health.
By enhancing insulin secretion in response to meals, reducing glucagon concentrations, and slowing gastric emptying, Tirzepatide peptide aids in stabilizing blood glucose levels. However, its use requires careful consideration of associated side effects such as nausea, diarrhea, and the potential increased risk of pancreatitis, emphasizing the need for healthcare providers to monitor patients closely during treatment.
🛻 Free Shipping on orders over $1000
Dragon Survodutide peptide is an investigational therapeutic agent under development that combines mechanisms targeting both appetite regulation and metabolic processes.
It is categorized as a dual GLP-1 and glucagon receptor agonist, functioning by influencing pathways involved in energy balance and glycemic control. This compound has been studied primarily for its potential applications in managing obesity and related metabolic disorders.
While its efficacy and safety are promising in preliminary trials, further rigorous clinical evaluation is essential to determine its long-term effects and appropriate use cases.
🛻 Free Shipping on orders over $1000
